Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective
Authors:
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29 (9) , 1310-1317
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Astellas Pharma US
- AbbVie
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Shire
- Pfizer
- Novartis
This publication has 23 references indexed in Scilit:
- Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCirculation: Heart Failure, 2016
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With HypertensionHypertension, 2014
- Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)European Journal of Heart Failure, 2013
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialThe Lancet, 2012
- Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in AustraliaBMJ Open, 2012
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyThe Lancet, 2010
- Cost-Effectiveness Analysis and the Consistency of Decision MakingPharmacoEconomics, 2001
- Methods in health service research: Handling uncertainty in economic evaluations of healthcare interventionsBMJ, 1999
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998